Jonathan Young - Jun 30, 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Stock symbol
AKRO
Transactions as of
Jun 30, 2025
Transactions value $
$21,243
Form type
4
Date filed
7/2/2025, 06:00 PM
Previous filing
Jun 20, 2025
Next filing
Aug 13, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Young Jonathan Chief Operating Officer C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO /s/ Jonathan Young 2025-07-02 0001779805

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Award $21.2K +890 +0.45% $23.87 197K Jun 30, 2025 Direct F1, F2
holding AKRO Common Stock 20K Jun 30, 2025 By EA Irrevocable Trust F3
holding AKRO Common Stock 20K Jun 30, 2025 By CM Irrevocable Trust F3
holding AKRO Common Stock 20K Jun 30, 2025 By JL Irrevocable Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dr. Young is voluntarily reporting the acquisition of these shares on June 30, 2025 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2 In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on January 2, 2025.
F3 These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.